Sarah Oelsner
Frankfurt Am Main, HE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
Journal: International journal of cancer
Published: September 21, 2018
Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children.
Journal: Oncotarget
Published: April 04, 2017
Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity.
Journal: Frontiers in immunology
Published: March 10, 2017
Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Journal: International journal of cancer
Published: February 29, 2016
Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.
Journal: Oncoimmunology
Published: September 14, 2015
SMAC Mimetic BV6 Enables Sensitization of Resistant Tumor Cells but also Affects Cytokine-Induced Killer (CIK) Cells: A Potential Challenge for Combination Therapy.
Journal: Frontiers in pediatrics
Published: April 15, 2014
Drug handling in a paediatric intensive care unit--can errors be prevented by a three-step intervention?
Journal: Klinische Padiatrie
Published: April 02, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026